Literature DB >> 29299012

Tremor-Ataxia syndrome and primary ovarian insufficiency in an FMR1 premutation carrier.

Wilmar Saldarriaga-Gil1, Tatiana Rodriguez-Guerrero2, Andres Fandiño-Losada3, Julian Ramirez-Cheyne1.   

Abstract

INTRODUCTION: The FMR1 gene has four allelic variants according to the number of repeats of the CGG triplet. Premutation carriers with between 55 and 200 repeats are susceptible to developing pathologies such as tremor and ataxia syndrome (FXTAS) and fragile X-associated primary ovarian insufficiency (FXPOI) syndrome. CASE DESCRIPTION: The patient was a 53-year-old female farmer with severe tremor in the upper limbs at rest that worsens with movement, tremor in the jaw and tongue, and generalized cerebral atrophy. She is a carrier of the FMR1 premutation diagnosed by PCR and Southern Blot, complying with the clinical and radiological criteria of FXTAS, and in addition, has a history of vagal symptoms suggestive of ovarian failure and menstrual cycle disorders that led to hysterectomy at age 33 and was subsequently diagnosed with FXPOI.
CONCLUSION: An unusual case of FXTAS and FXPOI complying with clinical and radiological criteria is reported in a premutation carrier of the FMR1 gene.

Entities:  

Keywords:  Ataxia/complications; Ataxia/diagnosis; Ataxia/genetics; FMR1gen; FXPOI; FXTAS; Fragile X Tremor Ataxia Syndrome

Mesh:

Substances:

Year:  2017        PMID: 29299012      PMCID: PMC5687867          DOI: 10.25100/cm.v48i3.3019

Source DB:  PubMed          Journal:  Colomb Med (Cali)        ISSN: 0120-8322


  14 in total

1.  Evidence of early ovarian aging in fragile X premutation carriers.

Authors:  C K Welt; P C Smith; A E Taylor
Journal:  J Clin Endocrinol Metab       Date:  2004-09       Impact factor: 5.958

2.  Symptomatic treatment in the fragile X-associated tremor/ataxia syndrome.

Authors:  Deborah A Hall; Elizabeth Berry-Kravis; Randi J Hagerman; Paul J Hagerman; Cathlin D Rice; Maureen A Leehey
Journal:  Mov Disord       Date:  2006-10       Impact factor: 10.338

3.  Clinically significant psychiatric symptoms among male carriers of the fragile X premutation, with and without FXTAS, and the mediating influence of executive functioning.

Authors:  Jim Grigsby; Angela G Brega; Rachael E Bennett; James A Bourgeois; Andreea L Seritan; Glenn K Goodrich; Randi J Hagerman
Journal:  Clin Neuropsychol       Date:  2016-06-29       Impact factor: 3.535

Review 4.  The FRAXopathies: definition, overview, and update.

Authors:  Filomena Pirozzi; Elisabetta Tabolacci; Giovanni Neri
Journal:  Am J Med Genet A       Date:  2011-07-07       Impact factor: 2.802

Review 5.  Epidemiology of fragile X syndrome: a systematic review and meta-analysis.

Authors:  Jessica Hunter; Oliver Rivero-Arias; Angel Angelov; Edward Kim; Iain Fotheringham; Jose Leal
Journal:  Am J Med Genet A       Date:  2014-04-03       Impact factor: 2.802

Review 6.  Fragile X syndrome.

Authors:  Wilmar Saldarriaga; Flora Tassone; Laura Yuriko González-Teshima; Jose Vicente Forero-Forero; Sebastián Ayala-Zapata; Randi Hagerman
Journal:  Colomb Med (Cali)       Date:  2014-12-30

Review 7.  Fragile X-associated tremor/ataxia syndrome - features, mechanisms and management.

Authors:  Randi J Hagerman; Paul Hagerman
Journal:  Nat Rev Neurol       Date:  2016-06-24       Impact factor: 42.937

8.  Aging in Fragile X Premutation Carriers.

Authors:  Reymundo Lozano; Naomi Saito; Dallas Reed; Marwa Eldeeb; Andrea Schneider; David Hessl; Flora Tassone; Laurel Beckett; Randi Hagerman
Journal:  Cerebellum       Date:  2016-10       Impact factor: 3.847

9.  Phenobarbital use and neurological problems in FMR1 premutation carriers.

Authors:  Wilmar Saldarriaga; Pamela Lein; Laura Yuriko González Teshima; Carolina Isaza; Lina Rosa; Andrew Polyak; Randi Hagerman; Santhosh Girirajan; Marisol Silva; Flora Tassone
Journal:  Neurotoxicology       Date:  2016-01-21       Impact factor: 4.294

Review 10.  From FMRP function to potential therapies for fragile X syndrome.

Authors:  Ferzin Sethna; Changjong Moon; Hongbing Wang
Journal:  Neurochem Res       Date:  2013-12-18       Impact factor: 3.996

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.